Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, explains how clinicians may treat patients with gliomas of different ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

This metabolite disrupts normal cellular function and promotes tumor growth. Vorasidenib, a novel IDH inhibitor, works by deactivating the mutated IDH1/2 enzymes, halting the production of ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

In an interview with THE WEEK, Professor Chuan He, lead researcher at the University of Chicago, talks about the new findings ...

with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult ...

“We were surprised to discover that KMT could work synergistically with the IDH1 mutation to simultaneously target ... using KMT and the a pan-glutaminase inhibitor—known as 6-diazo-5-oxo-L-norleucine ...